Leukapheresis Market in Europe: 2021 Edition

October 2021 | 71 pages | ID: LAC38130DC38EN
Gen Consulting Company

Abstracts

Leukapheresis is a laboratory procedure in which white blood cells are separated from a sample of blood. It is the first step in a treatment called CAR (chimeric antigen receptor) T-cell therapy. According to market research study published by Gen Consulting Company, the market size of the leukapheresis industry in Europe is expected to rise by USD 17 million with a CAGR of 6.9% by the end of 2027.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into leukapheresis market in Europe. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments.

The leukapheresis market is segmented on the basis of product, application, end user, and country. The leukapheresis market is segmented as below:

By product:

• leukapheresis devices
• leukapheresis disposables

By application:

• research
• therapies

By end user:

• blood centers
• hospitals & infusion centers
• enterprises
• academic & research institutes

By country:

• country
• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe

The report explores the recent developments and profiles of key vendors in the Leukapheresis Market in Europe, including AllCells Corporation, Asahi Kasei Corporation, BioIVT LLC, Fresenius SE & Co. KGaA, Haemonetics Corporation, HemaCare Corporation (Charles River Laboratories International, Inc.), Macopharma, STEMCELL Technologies Inc., StemExpress, LLC, Terumo Corporation, among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2017 to 2027 considering 2020 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the leukapheresis market in Europe.
• To classify and forecast the leukapheresis market in Europe based on product, application, end user, and country.
• To identify drivers and challenges for the leukapheresis market in Europe.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the leukapheresis market in Europe.
• To identify and analyze the profile of leading players operating in the leukapheresis market in Europe.

Why Choose This Report

• Gain a reliable outlook of the leukapheresis market in Europe forecasts from 2021 to 2027 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

1.1 Market definition
1.2 Key benefits
1.3 Market segment

PART 2. METHODOLOGY

2.1 Primary
2.2 Secondary

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

4.1 Introduction
4.2 Market dynamics
  4.2.1 Drivers
  4.2.2 Restraints

PART 5. LEUKAPHERESIS MARKET IN EUROPE, BY PRODUCT

5.1 Leukapheresis devices
  5.1.1 Market size and forecast
5.2 Leukapheresis disposables
  5.2.1 Market size and forecast

PART 6. LEUKAPHERESIS MARKET IN EUROPE, BY APPLICATION

6.1 Research
  6.1.1 Market size and forecast
6.2 Therapies
  6.2.1 Market size and forecast

PART 7. LEUKAPHERESIS MARKET IN EUROPE, BY END USER

7.1 Blood centers
  7.1.1 Market size and forecast
7.2 Hospitals & infusion centers
  7.2.1 Market size and forecast
7.3 Enterprises
  7.3.1 Market size and forecast
7.4 Academic & research institutes
  7.4.1 Market size and forecast

PART 8. LEUKAPHERESIS MARKET IN EUROPE, BY COUNTRY

8.1 UK
  8.1.1 Market size and forecast
8.2 Germany
  8.2.1 Market size and forecast
8.3 France
  8.3.1 Market size and forecast
8.4 Italy
  8.4.1 Market size and forecast
8.5 Spain
  8.5.1 Market size and forecast
8.6 Rest of Europe
  8.6.1 Market size and forecast

PART 9. KEY COMPETITOR PROFILES

9.1 AllCells Corporation
9.2 Asahi Kasei Corporation
9.3 BioIVT LLC
9.4 Fresenius SE & Co. KGaA
9.5 Haemonetics Corporation
9.6 HemaCare Corporation (Charles River Laboratories International, Inc.)
9.7 Macopharma
9.8 STEMCELL Technologies Inc.
9.9 StemExpress, LLC
9.10 Terumo Corporation
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER
ABOUT GEN CONSULTING COMPANY